Bold Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Vancouver, B.C. They develop novel metallotherapeutics for advanced cancers, with their lead candidate BOLD‑100—a ruthenium-based agent targeting unfolded protein response—currently in Phase 3 trials for metastatic colorectal and biliary tract cancers, following positive Phase 2 data in gastrointestinal cancers.